Search results for: Market Access
Filter search results
Claudio Jommi
19 April 2023
…Regolatorie e Market Access in Ambito Farmaceutico e Biotecnologico. He was Professor of Practice of Health Policy at SDA Bocconi School of Management, where he held the position of Director…
Around The World in HTAs: Egypt – The Road Ahead
31 July 2023
…facilitation of market access, and capacity and funding support. Making the process – and the resulting HTA reports- evidence-based and public once they are reviewed and finalized will be vital,…
Lavni Varyani
19 September 2025
…Group (now IQVIA), specializing in market access, pricing pathways, tendering and procurement processes, and commercial effectiveness. Her expertise includes the Saudi HTA system and spans diagnostics and high-value innovations across…
Three seminars forthcoming at OHE
12 May 2016
…of drugs, and how patent and price regulation regimes affect the speed of market access. He will show that price regulation delays launch, while longer and more extensive patent rights…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments
8 January 2021
…the other way around”. From a patient advocate perspective, she considers pragmatic access models that allow combining timely access with evidence generation, and addressing optimal sequencing of therapies, to be…
The Market for Biosimilars
25 January 2011
This publication expands on the series of posts published earlier on this blog. It reports on a seminar intended to encourage further thought about the distinguishing characteristics of the market…
OHE This Week: BioWales 2013, UK Medicines Market and EQ-5D in Asia
18 March 2013
…presentation on the economics of the market for medicines at City College in London. 21/22 March: Nancy Devlin will be in Singapore with EuroQol colleagues. Until 12 April, OHE is…
OHE at iHEA: HTA in Emerging Markets, Personalised Medicine, EQ-5D mapping
6 August 2013
…Adrian presented a paper examining the role of health technology assessment (HTA) (slides below). Placing the Evolution of HTA In Emerging Markets in Context of Health System Development from Office…
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
1 July 2018
…dynamic inefficiency or a suboptimal (too low) investment in innovation. However, too much IP protection might grant the originator market power for an excessive period. Such market power enables prices…